Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data? What to know.

Regeneron Pharmaceuticals (REGN) reported interim results from a mid-stage trial testing combinations of semaglutide with experimental antibodies, trevogrumab and garetosmab, for treating obesity.

TARRYTOWN, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the ...

Regeneron Pharmaceuticals announced its sixth inclusion in the Dow Jones Sustainability World Index, reflecting strong corporate responsibility and governance.

We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes.

I’ll admit to being surprised initially by the mid-month announcement that Regeneron Pharmaceuticals planned to buy out of bankruptcy most of the assets of 23andMe.

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

Discover the upcoming changes in the Russell 3000 Index as FTSE Russell announces new tech company additions and removals.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.